Drug intelligence / Profile preview

RO5468924

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral (as Metabolite Formed After Oral Administration Of Alectinib)

Overview

RO5468924 is the major pharmacologically active metabolite of alectinib, a small molecule tyrosine kinase inhibitor. It is generated in vivo after administration of alectinib and retains similar in vitro biological activity against its target, namely the rearranged during transfection (RET) tyrosine kinase, and is responsible for a substantial share of alectinib’s clinical efficacy. The metabolite is characterized by similar pharmacokinetic and pharmacodynamic properties to the parent compound and is monitored in plasma alongside alectinib in pharmacokinetic studies[1][3].

Other names: RO5428924RO-5428924RO 5428924M4M-4M 4

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on RO5468924.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO5468924.

Explore the full profile